Sanofi is poised for a new chapter under the leadership of incoming CEO Belén Garijo, starting her tenure amidst a significant revenue boost in the first quarter of 2026. The company’s impressive performance is largely attributed to the continued success of its immunology blockbuster, Dupixent, as well as the newly acquired hepatitis B vaccines.
Revenue Growth Highlights
In the early months of 2026, Sanofi reported a remarkable 13.6% increase in revenues, reaching just over €10.5 billion when adjusted for constant exchange rates. Dupixent, a key driver of this growth, saw its sales surge by 30.8%, totaling €4.2 billion. This sustained momentum after nearly a decade on the market reinforces Dupixent’s status as a cash-cow product for the company.
Impact of Recent Acquisitions
The acquisition of Dynavax for $2.5 billion last year has begun to bear fruit, contributing to a 2.1% rise in vaccine sales, amounting to €1.3 billion. The inclusion of the Heplisav-B range of adult hepatitis B shots has played a crucial role in this growth, showcasing the effectiveness of Sanofi’s strategic acquisitions.
Diversification of Product Portfolio
Encouraging signs are emerging that Sanofi’s dependency on Dupixent may be easing. A range of recently launched products, such as the long-acting hemophilia A therapy Altuviiio and the type 1 diabetes treatment Tzield, has collectively grown by nearly 50%, generating €1.1 billion in sales. This diversification reflects Sanofi’s commitment to expanding its product offerings and reducing reliance on any single medication.
Leadership Transition
Belén Garijo, formerly the CEO of Merck KGaA, is set to officially take the helm of Sanofi on April 29. Her appointment follows the departure of Paul Hudson, whose six-year tenure ended without a renewal of his contract. Reports suggest that Hudson’s increased spending on research and development in anticipation of Dupixent’s patent expiration around 2030 led to dissatisfaction among board members.
Regulatory Approvals and Future Outlook
Interim CEO Olivier Charmeil noted that business development efforts have mirrored the financial success achieved in the first quarter. The company received five regulatory approvals for several treatments, including Dupixent and Rezurock, alongside promising data from clinical trials for therapies targeting Gaucher disease and chronic rhinosinusitis with nasal polyps. However, setbacks in trials for both Fabry disease and atopic dermatitis have tempered expectations for some projects.
Financial Guidance and Expectations
Charmeil reiterated the company’s growth outlook for 2026, projecting a high single-digit percentage increase in sales and a slightly faster growth rate for business earnings per share at constant exchange rates. This guidance reflects a commitment to maintaining profitability while navigating the evolving pharmaceutical landscape.
Anticipated Approvals in 2026
As Garijo steps into her role, Sanofi anticipates several additional approvals in 2026. These include an oral BTK inhibitor for secondary progressive multiple sclerosis, a new subcutaneous formulation of the multiple myeloma treatment Sarclisa, and a rabies vaccine in development.
In conclusion, Sanofi’s incoming leadership is set against a backdrop of significant revenue growth and strategic advancements. With a strengthened product portfolio and a forward-looking approach to regulatory approvals, the company is well-positioned to navigate the challenges of the pharmaceutical industry. The transition to Garijo’s leadership marks a pivotal moment, promising continued innovation and success for Sanofi.
- Strong revenue growth driven by Dupixent and hepatitis B vaccines.
- Recent acquisitions are beginning to yield positive results.
- Sanofi is diversifying its portfolio to reduce reliance on key products.
- Leadership changes may steer the company in new strategic directions.
- Continued focus on regulatory approvals and innovation in 2026.
Read more → pharmaphorum.com